The drug: Plavix
The companies: Sanofi/Bristol-Myers Squibb
Estimated worldwide sales for 2012: $5.11 billion

Things are looking grim for Bristol-Myers Squibb ($BMY) and Sanofi's ($SNY) top-selling blood thinner Plavix. In the first quarter of this year, Plavix was the best-selling drug in America, jumping 3% to $1.62 billion. Then, May, the generics arrived.

And sales immediately slumped. BMS' Plavix revenues nosedived by 60% during the second quarter, thanks to those copycat rivals. Co-pay discounts may have kept some Plavix users on the branded version, but Bristol-Myers wasn't expecting much; it pulled back from actively promoting the drug or the co-pay program. Now, Plavix revenue is expected to drop more than $4 billion this year, falling well short of the $9.3 billion Plavix brought in last year.

The decline in sales prompted Sanofi and Bristol-Myers to rework their Plavix deal. Under a new agreement inked this month, Sanofi grabs worldwide Plavix rights, except for the U.S. and Puerto Rico. Bristol-Myers will hang on to those at least through 2018.

For more:
Sanofi, Bristol revamp Plavix partnership for post-patent world
Plavix tops U.S. sales ranks, but not for long
AZ puts Brilinta up for another head-to-head fight with Plavix
With Plavix gone generic, payers aim to cut Effient, Brilinta


Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.